<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical management and monitoring during antifungal therapy for cryptococcal meningoencephalitis in persons with HIV</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Gary M Cox, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John R Perfect, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Bartlett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Oct 11, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H14913496"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Cryptococcal meningoencephalitis is a serious opportunistic infection that is seen primarily among patients with untreated AIDS [<a href="#rid1">1</a>]. The initial preferred approach to the patient with cryptococcal meningoencephalitis includes combination antifungal therapy with amphotericin B plus <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (for the induction phase of therapy) followed by <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (for the consolidation and maintenance phases). During therapy, patients should be monitored for recurrence of clinical symptoms that may suggest increased intracranial pressure, relapse of infection (from lack of adherence or drug resistance), adverse events related to antifungal therapy, and immune recovery syndromes secondary to antiretroviral therapy (ART).</p><p>This topic is devoted to clinical monitoring of the HIV-infected host with cryptococcal meningoencephalitis. Topic reviews that discuss the epidemiology, clinical manifestations, diagnosis, and treatment of disease are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV"</a> and  <a class="medical medical_review" href="/z/d/html/2448.html" rel="external">"Microbiology and epidemiology of Cryptococcus neoformans infection"</a> and  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a> and  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>.)</p><p class="headingAnchor" id="H448439184"><span class="h1">MONITORING ON THERAPY</span></p><p class="headingAnchor" id="H14913503"><span class="h2">Monitoring for drug toxicity</span></p><p class="headingAnchor" id="H14913510"><span class="h3">Amphotericin B</span><span class="headingEndMark"> — </span>Infusion-related reactions, particularly nausea, vomiting, chills, and rigors, are common with intravenous (IV) <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> administration and usually occur either during infusion (within 15 minutes to 3 hours following initiation) or immediately following administration of the dose. Patients with infusion-related reactions may be pretreated with <a class="drug drug_general" data-topicid="9242" href="/z/d/drug information/9242.html" rel="external">acetaminophen</a>, <a class="drug drug_general" data-topicid="9369" href="/z/d/drug information/9369.html" rel="external">diphenhydramine</a>, or corticosteroids administered approximately 30 minutes before infusion. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Infusion-related reactions'</a>.)</p><p>Amphotericin B is associated with renal insufficiency, hypokalemia, hypomagnesemia, hypocalcemia, and hypophosphatemia. Thus, patients treated with amphotericin B should have daily monitoring of serum creatinine and electrolytes. Many patients require significant amounts of potassium and/or magnesium supplementation during therapy and hydration with normal <a class="drug drug_general" data-topicid="9929" href="/z/d/drug information/9929.html" rel="external">saline</a> during amphotericin B infusions. A more detailed discussion of the adverse effects of amphotericin is presented elsewhere. (See  <a class="medical medical_review" href="/z/d/html/476.html" rel="external">"Pharmacology of amphotericin B", section on 'Adverse effects'</a>.) </p><p>A lipid-based formulation of amphotericin B has become the preferred polyene in resource-available environments and should be specifically used for patients who develop renal insufficiency (eg, plasma creatinine concentration exceeds 2.5 mg/dL) while receiving <a class="drug drug_general" data-topicid="8701" href="/z/d/drug information/8701.html" rel="external">amphotericin B deoxycholate</a> or if there are concerns about having to interrupt induction therapy due to toxicity. If this is not possible, the dose of amphotericin B deoxycholate can be reduced by 50 percent or given every other day. It is critical that there is no interruption of the combination regimen during the two-week induction period. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Induction therapy'</a>.)</p><p class="headingAnchor" id="H14913517"><span class="h3">Flucytosine</span><span class="headingEndMark"> — </span>The most significant toxicities of <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> (5-FC) are hematologic. In particular, leukopenia and thrombocytopenia can limit its use, although dose reduction may ameliorate hematologic toxicities. </p><p>In addition, renal dysfunction caused by the concomitant administration of nephrotoxic agents, such as amphotericin B, can lead to <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> accumulation and further contribute to dose-related toxicity [<a href="#rid2">2</a>]. Thus, dose reduction is required for patients with renal insufficiency. Dosing recommendations for flucytosine are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Dosing'</a>.) </p><p>Ideally, serum drug levels of <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> should be monitored in patients with renal insufficiency [<a href="#rid3">3</a>] (see  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Serum concentration monitoring'</a>). However, since flucytosine levels are not readily available in many clinical settings, monitoring for bone marrow toxicity with a thrice weekly complete blood count can act as a surrogate of drug accumulation. For example, dose reduction or discontinuation of flucytosine should be considered when the absolute neutrophil count declines to &lt;500 cells/microL or the platelet count drops below 75,000/microL. (See  <a class="medical medical_review" href="/z/d/html/472.html" rel="external">"Pharmacology of flucytosine (5-FC)", section on 'Renal dysfunction'</a>.)</p><p>Approximately 5 percent of patients develop elevations in serum hepatic aminotransferases or alkaline phosphatase. Gastrointestinal complaints such as nausea, vomiting, and diarrhea also occur.</p><p class="headingAnchor" id="H14913524"><span class="h3">Fluconazole</span><span class="headingEndMark"> — </span>A minority of patients develop rash while receiving <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a>. Monitoring of aminotransferases is suggested in patients on long-term therapy. The risk of drug-induced liver injury increases with high doses (eg, &gt;800 mg daily). Alopecia and chapped lips have been reported following long courses of high-dose fluconazole, but they are reversible after drug discontinuation. Drug-drug interactions can indirectly cause toxicity issues with this azole. A more detailed discussion of adverse reactions related to fluconazole is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/495.html" rel="external">"Pharmacology of azoles", section on 'Adverse effects'</a>.)</p><p class="headingAnchor" id="H14913531"><span class="h2">Laboratory monitoring for fungal infection</span></p><p class="headingAnchor" id="H14913552"><span class="h3">Sterilization of cerebrospinal fluid</span><span class="headingEndMark"> — </span>We repeat a lumbar puncture (LP) for fungal culture after two weeks of induction antifungal therapy to confirm sterilization of the cerebrospinal fluid (CSF), even among patients who have clinically improved. The opening pressure should also be measured at that time. (See <a class="local">'Monitoring of intracranial pressure'</a> below.)</p><p>However, in resource-limited settings, it may be difficult to obtain a repeat LP. Guideline recommendations from the World Health Organization state that routine LP to monitor the response to induction therapy is not needed in middle- and low-income countries if the patient has evidence of clinical recovery [<a href="#rid4">4</a>].</p><p>For those receiving a regimen that uses a shortened duration of amphotericin B, we suggest an LP be done to assess the response sometime between 7 and 14 days after the last dose of polyene therapy. For those who have a positive culture, we would repeat induction therapy with the standard two-week regimen of amphotericin B plus <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a>  (<a class="graphic graphic_table graphicRef130859" href="/z/d/graphic/130859.html" rel="external">table 1</a>). </p><p>The evaluation and management of patients with positive cultures are found below. (See <a class="local">'Initial approach'</a> below and <a class="local">'Management of persistent or relapsing infection'</a> below.)</p><p>The impact of repeat LP in guiding the transition to consolidation therapy is presented separately. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Consolidation therapy'</a>.)</p><p class="headingAnchor" id="H2828308209"><span class="h3">Monitoring of serum cryptococcal antigen</span><span class="headingEndMark"> — </span>We do<strong> not</strong> perform serial monitoring of serum cryptococcal antigen (CrAg) in patients being treated for cryptococcal meningoencephalitis. Changes in CrAg titer do not correlate with clinical improvement during induction or consolidation therapy [<a href="#rid5">5</a>]. </p><p>However, we monitor serum CrAg in patients who have discontinued maintenance therapy if their CD4 count is &lt;200 cells/microL. Maintenance therapy can be discontinued in patients receiving antiretroviral therapy if they have received at least one year of antifungal therapy and have attained both a CD4 count &gt;100 cells/microL and virologic suppression for at least three months. In the absence of virologic monitoring, maintenance therapy should be continued for one year and until the CD4 count is &gt;200 cells/microL. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Maintenance therapy'</a>.) </p><p>The frequency and duration of CrAg monitoring in patients who have discontinued maintenance therapy is unclear. We measure the serum CrAg when maintenance therapy is discontinued and then every three months after that until the CD4 count is &gt;200 cells/microL. We restart maintenance doses of <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (ie, 200 mg daily) in asymptomatic patients who meet the following criteria: </p><p class="bulletIndent1"><span class="glyph">●</span>The CrAg becomes detectable (ie, serum CrAg was negative at end of treatment).</p><p class="bulletIndent1"><span class="glyph">●</span>There is a ≥4-fold rise in the CrAg titer compared with the end-of-treatment level.</p><p></p><p>Patients who develop symptoms should be reassessed for clinical disease. (See <a class="local">'Evaluation for treatment failure'</a> below.) </p><p class="headingAnchor" id="H645246"><span class="h2">Monitoring of intracranial pressure</span><span class="headingEndMark"> — </span>Patients with AIDS and cryptococcal meningoencephalitis tend to have a high fungal burden in the CSF, which can lead to increased intracranial pressure (ICP) (defined as &gt;20 cm CSF) [<a href="#rid3">3,6-12</a>]. Most patients have signs and symptoms consistent with increased ICP (eg, headache, clouding of sensorium, visual and hearing loss, ataxia, cranial nerve palsies, and papilledema) [<a href="#rid6">6,8-14</a>]; however, some individuals are asymptomatic and, therefore, difficult to assess clinically. </p><p>The mechanism of increased ICP in cryptococcal meningoencephalitis is not completely understood. Potential etiologies include increased vascular permeability secondary to cytokine-induced inflammation and clogging of arachnoid villi with fungal antigen and/or yeasts, leading to impairment of CSF resorptive function [<a href="#rid13">13</a>]. One autopsy study demonstrated infiltration of <em>Cryptococcus</em>, inflammatory infiltrates, and fibrosis within arachnoid cells [<a href="#rid15">15</a>].</p><p class="headingAnchor" id="H22136975"><span class="h3">When to measure the ICP</span><span class="headingEndMark"> — </span>The intracranial pressure (ICP) should be measured at the time of the initial LP. Untreated increased ICP can cause significant morbidity, permanent neurologic disability, or mortality [<a href="#rid13">13</a>]. (See  <a class="medical medical_review" href="/z/d/html/3757.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of Cryptococcus neoformans meningoencephalitis in patients with HIV", section on 'Diagnosis'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>After the initial LP, the ICP is typically measured when repeat fungal cultures are obtained after two weeks of induction therapy. (See <a class="local">'Sterilization of cerebrospinal fluid'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A repeat LP and measurement of ICP should be performed sooner in patients who have persistent symptoms during induction therapy, especially if they are severe or worsening. This is particularly important if the baseline ICP was elevated or not measured. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A repeat LP and measurement of ICP should also be performed in any patient who has recurrent symptoms after initial improvement. (See <a class="local">'Evaluation for treatment failure'</a> below.)</p><p></p><p>The management of patients with increased ICP and/or persistent symptoms is discussed below. (See <a class="local">'Management'</a> below and <a class="local">'Management of IRIS'</a> below and <a class="local">'Management of persistent or relapsing infection'</a> below.)</p><p class="headingAnchor" id="H645332"><span class="h3">Management</span><span class="headingEndMark"> — </span>Increased ICP in patients with cryptococcal meningoencephalitis should be managed aggressively to decrease mortality [<a href="#rid16">16,17</a>]. The initial management of patients with increased ICP is presented in a separate topic review. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Management of increased intracranial pressure'</a>.) </p><p>A patient who has a continued requirement for serial LPs for management of increased ICP after appropriate antifungal therapy will likely need a permanent ventriculoperitoneal shunt [<a href="#rid13">13,18</a>]. This device should ideally be placed after the patient has completed the induction course of antifungal therapy (ie, while the patient is receiving consolidation or maintenance therapy) [<a href="#rid14">14,16,19</a>].</p><p>Increased ICP has been associated with persistently positive cultures and an increased risk of mortality. As an example, in one large trial, 93 percent of deaths that occurred within the first two weeks of therapy were associated with increased ICP [<a href="#rid6">6,18</a>].</p><p class="headingAnchor" id="H21602481"><span class="h1">EVALUATION FOR TREATMENT FAILURE</span><span class="headingEndMark"> — </span>During treatment, there may be three different outcomes:</p><p class="bulletIndent1"><span class="glyph">●</span>Successful induction and consolidation antifungal therapy with switch to ongoing maintenance therapy with clinical improvement.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Successful induction and consolidation antifungal therapy followed by recurrent symptoms during maintenance therapy, consistent with either culture-positive relapse of infection or an immune reconstitution inflammatory syndrome (IRIS).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Unsuccessful induction or consolidation with antifungal therapy with persistent documentation of viable <em>Cryptococcus</em> in the cerebrospinal fluid (CSF) for four weeks or longer; this outcome should prompt questions regarding adherence, drug resistance, or poor host response. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Consolidation regimen'</a>.)</p><p></p><p>The evaluation of patients with possible treatment failure will be discussed in this section. The management of patients with persistent or relapsed infection is discussed below. (See <a class="local">'Management of persistent or relapsing infection'</a> below.)</p><p class="headingAnchor" id="H3372084315"><span class="h2">Initial approach</span><span class="headingEndMark"> — </span>Treatment failure can be seen in asymptomatic patients who have a positive culture on routine lumbar puncture (LP) performed after induction therapy and in patients with persistent or new symptoms.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Asymptomatic patients</strong> – Asymptomatic patients with a persistent positive CSF culture should be assessed for adherence to the antimicrobial regimen. In addition, drug resistance testing should be performed on the CSF isolate from the repeat LP that demonstrated persistent infection and compared to the original isolate. (See <a class="local">'Drug resistance testing'</a> below.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with persistent or new symptoms</strong> – In patients with symptoms (eg, headache) that are persistent or arise after initial clinical improvement, an LP should be performed to rule out the possibility of increased intracranial pressure (ICP) and assess for fungal growth. (See <a class="local">'When to measure the ICP'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If the patient has initiated antiretroviral therapy (ART), increased ICP and pleocytosis in the setting of a sterile culture and/or negative polymerase chain reaction (PCR) test are most likely related to paradoxical IRIS. (See <a class="local">'Immune reconstitution inflammatory syndrome'</a> below.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Increased ICP may also be due to persistent or relapsed fungal infection as suggested by a positive culture. Antifungal drug resistance testing should be performed on the isolate from the repeat LP. (See <a class="local">'Drug resistance testing'</a> below and <a class="local">'Management of persistent or relapsing infection'</a> below.)</p><p></p><p>It is important assess and address barriers to adherence (eg, lack of understanding for implications of untreated disease, psychosocial issues, adverse side effects) in all patients with persistent or relapsing infection. Patients who have difficulty taking their medications as prescribed should also have HIV virologic testing to confirm virologic control since they are also at risk for developing resistance to their ART regimen.</p><p class="headingAnchor" id="H829492286"><span class="h2">Drug resistance testing</span><span class="headingEndMark"> — </span>To assess for antifungal resistance, an on-treatment cryptococcal isolate should be obtained and evaluated for changes in the minimum inhibitory concentration (MIC) against the antifungal agent that is being administered. It should also be compared to the original (pre-treatment) isolate; specifically, a threefold increase in MIC from the pretreatment isolate to the on-treatment isolate would suggest emerging drug resistance [<a href="#rid20">20</a>]. An absolute MIC of ≥16 mcg/mL for <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> or ≥32 mcg/mL for <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a> for a single isolate may also be suggestive of drug resistance; however, there remains no precise in vitro susceptibility break point for strain resistance in cryptococcosis.</p><p class="headingAnchor" id="H1785225844"><span class="h1">MANAGEMENT OF PERSISTENT OR RELAPSING INFECTION</span><span class="headingEndMark"> — </span>Management of persistent or relapsing infection depends upon the potential cause (eg, adherence, drug resistance, or poor host response). As examples:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing infection with susceptible isolate</strong> – If no drug resistance is documented, the patient should undergo repeat induction/consolidation therapy followed by maintenance <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> at the usual dose with close follow-up to monitor adherence. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Relapsing or persistent infection with drug-resistant isolate</strong> – When drug resistance is a concern or documented during consolidative therapy, the optimal approach is unclear. The use of alternative therapies may be reasonable, such as <a class="drug drug_general" data-topicid="10118" href="/z/d/drug information/10118.html" rel="external">voriconazole</a> (200 to 400 mg twice daily), <a class="drug drug_general" data-topicid="9479" href="/z/d/drug information/9479.html" rel="external">posaconazole</a> tablets (loading dose of 300 mg every 12 hours on the first day, followed by 300 mg daily), or <a class="drug drug_general" data-topicid="100324" href="/z/d/drug information/100324.html" rel="external">isavuconazole</a> (loading dose of 200 mg every eight hours for six doses, followed by 200 mg daily); however, the use of these agents is based on limited data from case series [<a href="#rid3">3,21-23</a>]. Prior to initiation, the in vitro susceptibility of the recent isolate must be evaluated to all antifungal agents and compared with the initial or pre-treatment isolate. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Persistent/refractory disease</strong> – In patients with a positive culture after two weeks, additional therapy is indicated before transitioning to consolidation therapy. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Consolidation therapy'</a>.)</p><p></p><p class="bulletIndent1">We typically continue treatment with a preferred combination induction therapy regimen  (<a class="graphic graphic_table graphicRef130859" href="/z/d/graphic/130859.html" rel="external">table 1</a>) and repeat an LP after two more weeks to evaluate for culture sterility. However, if the patient is asymptomatic and never had any issues with elevated intracranial pressures, it is reasonable to treat with a two-week course of high-dose <a class="drug drug_general" data-topicid="8450" href="/z/d/drug information/8450.html" rel="external">fluconazole</a> (1200 mg a day for those with normal renal function) followed by another LP.</p><p></p><p class="bulletIndent1">However, some patients have refractory disease (eg, positive cultures and no apparent direct resistance by in vitro testing after four weeks of therapy) despite optimal antifungal management and subsequent initiation of ART. For patients with refractory culture-positive cryptococcal disease on ART for greater than four weeks, adjunctive immunologic therapy using interferon gamma at 100 mcg subcutaneously three times per week in combination with antifungal therapy may be beneficial [<a href="#rid24">24,25</a>]. Interferon gamma has not been used in any large trials for refractory disease, but when used as part of initial induction therapy for cryptococcal meningitis, it has been shown to significantly augment the fungicidal activity of standard therapy [<a href="#rid24">24,25</a>]. The duration of interferon gamma adjunctive therapy has been used for as long as ten weeks, and it has not been shown to adversely affect underlying HIV infection. We would use interferon gamma until the cerebrospinal fluid is sterilized, or for ten weeks, whichever comes first.</p><p></p><p>Management of increased intracranial pressure is also important in patients with persistent or relapsing infection, as described above. (See <a class="local">'Management'</a> above.)</p><p class="headingAnchor" id="H14913615"><span class="h1">IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME</span><span class="headingEndMark"> — </span>Immune recovery with potent antiretroviral medications is key to the management of patients with cryptococcal meningoencephalitis. However, the initiation of antiretroviral therapy (ART) can also lead to complications such as immune reconstitution inflammatory syndrome (IRIS). To reduce this risk, ART should be started between 2 and 10 weeks after antifungal therapy has been initiated. Deciding when to initiate ART within this window depends in part upon the clinical setting and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'When to initiate antiretroviral therapy'</a>.)</p><p>However, even with delayed ART, IRIS can still occur. This section will review the clinical manifestations and management of patients with IRIS.</p><p class="headingAnchor" id="H14913636"><span class="h2">General background</span><span class="headingEndMark"> — </span>The term "immune reconstitution inflammatory syndrome" (IRIS) describes a collection of inflammatory disorders associated with paradoxical worsening of a pre-existing treated infectious process following the initiation of potent ART in HIV-infected individuals [<a href="#rid26">26-32</a>]. If immune function improves rapidly following the commencement of ART, systemic or local inflammatory reactions may occur at the site or sites of the pre-existing infection (unmasking). According to one meta-analysis, IRIS occurred in approximately 13 percent of all immunosuppressed patients initiating ART, but occurred with increased frequency among those with cryptococcal disease (ie, 20 percent) [<a href="#rid33">33</a>]. The inflammatory reaction is usually self-limited, especially if the pre-existing infection is effectively treated. However, long-term sequelae and fatal outcomes may occur, particularly when the inflammatory reaction occurs within the central nervous system (CNS). (See  <a class="medical medical_review" href="/z/d/html/3762.html" rel="external">"Immune reconstitution inflammatory syndrome"</a>.)</p><p class="headingAnchor" id="H14913643"><span class="h2">Symptoms and signs</span><span class="headingEndMark"> — </span>Certain patients who have experienced an initial clinical improvement on antifungal therapy will develop symptoms of cryptococcal IRIS after initiating ART, potentially leading to significant morbidity and mortality [<a href="#rid33">33,34</a>]. These symptoms can be localized to the CNS and are related to increased intracranial pressure (ICP):</p><p class="bulletIndent1"><span class="glyph">●</span>Headache </p><p class="bulletIndent1"><span class="glyph">●</span>Nausea and vomiting</p><p class="bulletIndent1"><span class="glyph">●</span>Decreased alertness</p><p></p><p>Additional non-CNS manifestations can include lymphadenopathy, pneumonitis, or ocular manifestations. Cryptococcosis is a disseminated infection; thus, paradoxical IRIS manifestations can reflect previously silent areas of disseminated infection. </p><p>Most cases of cryptococcal IRIS occur within the first three months after ART is initiated; however, late presentations (up to 10 months after ART is started) have also been reported [<a href="#rid35">35-37</a>]. A repeat lumbar puncture (LP) typically demonstrates sterile cerebrospinal fluid (CSF) cultures, reduced CrAg titers and negative polymerase chain reaction (PCR) results, and an inflammatory response that may be greater than baseline [<a href="#rid36">36</a>]. </p><p class="headingAnchor" id="H14913650"><span class="h2">Management of IRIS</span><span class="headingEndMark"> — </span>Most minor signs of immune reconstitution inflammatory syndrome (IRIS) resolve spontaneously after days to a few weeks. </p><p>However, symptomatic patients with CSF pleocytosis and increased ICP are at risk for herniation. Serial LPs are important in managing increased ICP and should be performed until stabilization of symptoms and normalization of ICP occurs; the exact timing of LP is determined on a case-by-case basis. Sometimes a lumbar drain or ventriculoperitoneal shunt is required. (See <a class="local">'Monitoring of intracranial pressure'</a> above.)</p><p>We and other experts also use glucocorticoids to treat patients with symptomatic increased ICP related to IRIS based upon case reports and extrapolation from other disease processes [<a href="#rid34">34,38</a>]. Since there are no controlled trials examining the use of glucocorticoids for IRIS, the dose and duration of treatment are unclear. We typically initiate 0.5 to 1 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> daily (or equivalent) and then taper the dose over two to six weeks [<a href="#rid3">3</a>]. A good alternative is to administer a <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> taper, such as the one that is used for the treatment of tuberculous meningitis [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/128001.html" rel="external">"Central nervous system tuberculosis: Treatment and prognosis", section on 'Glucocorticoids'</a>.) </p><p>Sometimes it is unclear if the patient has IRIS or relapsed infection. In that setting, the approach to treatment must be individualized, and it may be reasonable to administer glucocorticoids and escalate antifungal therapy until the cultures are finalized. Such patients should be managed in conjunction with an infectious diseases specialist. </p><p>We do <strong>not</strong> routinely administer glucocorticoids at the start of cryptococcal meningoencephalitis treatment (which is often done in patients with tuberculous meningitis). Glucocorticoids do not appear to reduce the risk of IRIS, they can have a negative impact on the killing of yeasts in the CSF, and they can produce increased morbidity [<a href="#rid39">39</a>]. (See  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention", section on 'Overview'</a>.)</p><p>There are minimal data regarding the successful role for nonsteroidal anti-inflammatory agents or immunosuppressive biologicals such as anti-tumor necrosis factor inhibitors to control inflammation [<a href="#rid40">40</a>]. These therapies are typically used in the management of refractory IRIS.</p><p class="headingAnchor" id="H333031884"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/113059.html" rel="external">"Society guideline links: Cryptococcosis"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H14913664"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Treatment</strong> – Cryptococcal meningoencephalitis is a serious opportunistic infection that is seen among patients with untreated advanced AIDS. The management of cryptococcal meningoencephalitis involves combination antifungal therapy  (<a class="graphic graphic_table graphicRef130859" href="/z/d/graphic/130859.html" rel="external">table 1</a>), and is discussed in detail separately. (See <a class="local">'Introduction'</a> above and  <a class="medical medical_review" href="/z/d/html/83651.html" rel="external">"Cryptococcus neoformans meningoencephalitis in persons with HIV: Treatment and prevention"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring for drug toxicity</strong> – The antifungal drugs used in the treatment of cryptococcal meningoencephalitis can be associated with significant toxicity, particularly amphotericin B and <a class="drug drug_general" data-topicid="8451" href="/z/d/drug information/8451.html" rel="external">flucytosine</a>. Close laboratory monitoring is needed for renal insufficiency, hematologic abnormalities, and electrolyte disturbances during induction therapy. (See <a class="local">'Monitoring for drug toxicity'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluating response to therapy</strong> – For most patients, a lumbar puncture (LP) should be performed after two weeks of induction therapy to confirm sterilization of the cerebrospinal fluid (CSF) and to reassess intracranial pressure (ICP). We do <strong>not</strong> monitor serum cryptococcal antigen during treatment, since changes in this laboratory parameter do not correlate with clinical improvement. (See <a class="local">'Laboratory monitoring for fungal infection'</a> above and <a class="local">'Monitoring of intracranial pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Monitoring ICP</strong> – For patients with persistent symptoms, or new symptoms after initial clinical improvement, an LP should be performed to rule out the possibility of increased ICP. Increased ICP may be related to the immune reconstitution inflammatory syndrome (IRIS) among patients who have initiated antiretroviral therapy, or due to persistent or relapsing infection, as suggested by a positive culture. (See <a class="local">'Monitoring of intracranial pressure'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to treatment failure</strong> – For patients with persistent or relapsing cryptococcal infection, the clinical management depends upon the suspected cause (eg, poor adherence, drug resistance, refractory disease). (See <a class="local">'Evaluation for treatment failure'</a> above and <a class="local">'Management of persistent or relapsing infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management of IRIS</strong> – For patients with IRIS, most minor signs resolve spontaneously after days to a few weeks. However, symptomatic patients with CSF pleocytosis and increased ICP are at risk for herniation. For such patients, serial LPs should be performed until stabilization of symptoms and normalization of ICP occurs. In addition, we suggest glucocorticoids (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Although the dose and duration are unclear, we typically initiate 0.5 to 1 mg/kg of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (or equivalent) daily and then taper the dose over two to six weeks. (See <a class="local">'Management of IRIS'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bamba S, Lortholary O, Sawadogo A, et al. Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy. AIDS 2012; 26:1039.</a></li><li><a class="nounderline abstract_t">Vermes A, Guchelaar HJ, Dankert J. Prediction of flucytosine-induced thrombocytopenia using creatinine clearance. Chemotherapy 2000; 46:335.</a></li><li><a class="nounderline abstract_t">Perfect JR, Dismukes WE, Dromer F, et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2010; 50:291.</a></li><li class="breakAll">The World Health Organization. Guidelines for the diagnosis, prevention and management of cryptococcal disease in HIV-infected adults, adolescents, and children. http://apps.who.int/iris/bitstream/handle/10665/260399/9789241550277-eng.pdf;jsessionid=7A37044AC579D4A69EBBBF0B47BC60AF?sequence=1 (Accessed on March 19, 2021).</li><li><a class="nounderline abstract_t">Kabanda T, Siedner MJ, Klausner JD, et al. Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid. Clin Infect Dis 2014; 58:113.</a></li><li><a class="nounderline abstract_t">van der Horst CM, Saag MS, Cloud GA, et al. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group. N Engl J Med 1997; 337:15.</a></li><li><a class="nounderline abstract_t">Saag MS, Powderly WG, Cloud GA, et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group. N Engl J Med 1992; 326:83.</a></li><li><a class="nounderline abstract_t">Tang LM. Ventriculoperitoneal shunt in cryptococcal meningitis with hydrocephalus. Surg Neurol 1990; 33:314.</a></li><li><a class="nounderline abstract_t">Bach MC, Tally PW, Godofsky EW. Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension. Neurosurgery 1997; 41:1280.</a></li><li><a class="nounderline abstract_t">Claus JJ, Portegies P. Reversible blindness in AIDS-related cryptococcal meningitis. Clin Neurol Neurosurg 1998; 100:51.</a></li><li><a class="nounderline abstract_t">Fessler RD, Sobel J, Guyot L, et al. Management of elevated intracranial pressure in patients with Cryptococcal meningitis. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:137.</a></li><li><a class="nounderline abstract_t">Mylonakis E, Merriman NA, Rich JD, et al. Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis. Diagn Microbiol Infect Dis 1999; 34:111.</a></li><li><a class="nounderline abstract_t">Pappas PG. Managing cryptococcal meningitis is about handling the pressure. Clin Infect Dis 2005; 40:480.</a></li><li><a class="nounderline abstract_t">Shoham S, Cover C, Donegan N, et al. Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2005; 40:477.</a></li><li><a class="nounderline abstract_t">Loyse A, Wainwright H, Jarvis JN, et al. Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure. AIDS 2010; 24:405.</a></li><li><a class="nounderline abstract_t">Kambugu A, Meya DB, Rhein J, et al. Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy. Clin Infect Dis 2008; 46:1694.</a></li><li><a class="nounderline abstract_t">Rolfes MA, Hullsiek KH, Rhein J, et al. The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis. Clin Infect Dis 2014; 59:1607.</a></li><li><a class="nounderline abstract_t">Graybill JR, Sobel J, Saag M, et al. Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups. Clin Infect Dis 2000; 30:47.</a></li><li><a class="nounderline abstract_t">Newton PN, Thai le H, Tip NQ, et al. A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis. Clin Infect Dis 2002; 35:769.</a></li><li><a class="nounderline abstract_t">Aller AI, Martin-Mazuelos E, Lozano F, et al. Correlation of fluconazole MICs with clinical outcome in cryptococcal infection. Antimicrob Agents Chemother 2000; 44:1544.</a></li><li><a class="nounderline abstract_t">Pitisuttithum P, Negroni R, Graybill JR, et al. Activity of posaconazole in the treatment of central nervous system fungal infections. J Antimicrob Chemother 2005; 56:745.</a></li><li><a class="nounderline abstract_t">Perfect JR, Marr KA, Walsh TJ, et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122.</a></li><li><a class="nounderline abstract_t">Thompson GR 3rd, Rendon A, Ribeiro Dos Santos R, et al. Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses. Clin Infect Dis 2016; 63:356.</a></li><li><a class="nounderline abstract_t">Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185.</a></li><li><a class="nounderline abstract_t">Jarvis JN, Meintjes G, Rebe K, et al. Adjunctive interferon-γ immunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial. AIDS 2012; 26:1105.</a></li><li><a class="nounderline abstract_t">DeSimone JA, Pomerantz RJ, Babinchak TJ. Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy. Ann Intern Med 2000; 133:447.</a></li><li><a class="nounderline abstract_t">French MA, Lenzo N, John M, et al. Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy. HIV Med 2000; 1:107.</a></li><li><a class="nounderline abstract_t">Shelburne SA 3rd, Hamill RJ, Rodriguez-Barradas MC, et al. Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy. Medicine (Baltimore) 2002; 81:213.</a></li><li><a class="nounderline abstract_t">Michelet C, Arvieux C, François C, et al. Opportunistic infections occurring during highly active antiretroviral treatment. AIDS 1998; 12:1815.</a></li><li><a class="nounderline abstract_t">Hirsch HH, Kaufmann G, Sendi P, Battegay M. Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004; 38:1159.</a></li><li><a class="nounderline abstract_t">Shelburne SA, Montes M, Hamill RJ. Immune reconstitution inflammatory syndrome: more answers, more questions. J Antimicrob Chemother 2006; 57:167.</a></li><li><a class="nounderline abstract_t">Murdoch DM, Venter WD, Feldman C, Van Rie A. Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study. AIDS 2008; 22:601.</a></li><li><a class="nounderline abstract_t">Müller M, Wandel S, Colebunders R, et al. Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:251.</a></li><li><a class="nounderline abstract_t">Lortholary O, Fontanet A, Mémain N, et al. Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France. AIDS 2005; 19:1043.</a></li><li><a class="nounderline abstract_t">Bicanic T, Meintjes G, Rebe K, et al. Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study. J Acquir Immune Defic Syndr 2009; 51:130.</a></li><li><a class="nounderline abstract_t">Boulware DR, Meya DB, Bergemann TL, et al. Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study. PLoS Med 2010; 7:e1000384.</a></li><li><a class="nounderline abstract_t">Haddow LJ, Colebunders R, Meintjes G, et al. Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions. Lancet Infect Dis 2010; 10:791.</a></li><li><a class="nounderline abstract_t">Thwaites GE, Nguyen DB, Nguyen HD, et al. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med 2004; 351:1741.</a></li><li><a class="nounderline abstract_t">Beardsley J, Wolbers M, Kibengo FM, et al. Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis. N Engl J Med 2016; 374:542.</a></li><li><a class="nounderline abstract_t">Sitapati AM, Kao CL, Cachay ER, et al. Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab. Clin Infect Dis 2010; 50:e7.</a></li></ol></div><div id="topicVersionRevision">Topic 85376 Version 17.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22552479" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Decreasing incidence of cryptococcal meningitis in West Africa in the era of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10965099" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prediction of flucytosine-induced thrombocytopenia using creatinine clearance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047480" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20047480" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the Infectious Diseases Society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24065327" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Point-of-care diagnosis and prognostication of cryptococcal meningitis with the cryptococcal antigen lateral flow assay on cerebrospinal fluid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9203426" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1727236" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis. The NIAID Mycoses Study Group and the AIDS Clinical Trials Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2330532" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Ventriculoperitoneal shunt in cryptococcal meningitis with hydrocephalus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9402579" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Use of cerebrospinal fluid shunts in patients having acquired immunodeficiency syndrome with cryptococcal meningitis and uncontrollable intracranial hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9637206" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Reversible blindness in AIDS-related cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9473014" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Management of elevated intracranial pressure in patients with Cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10354860" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Use of cerebrospinal fluid shunt for the management of elevated intracranial pressure in a patient with active AIDS-related cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668875" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Managing cryptococcal meningitis is about handling the pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15668874" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Cryptococcus neoformans meningitis at 2 hospitals in Washington, D.C.: adherence of health care providers to published practice guidelines for the management of cryptococcal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19952714" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Histopathology of the arachnoid granulations and brain in HIV-associated cryptococcal meningitis: correlation with cerebrospinal fluid pressure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18433339" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Outcomes of cryptococcal meningitis in Uganda before and after the availability of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25057102" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : The effect of therapeutic lumbar punctures on acute mortality from cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10619732" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Diagnosis and management of increased intracranial pressure in patients with AIDS and cryptococcal meningitis. The NIAID Mycoses Study Group and AIDS Cooperative Treatment Groups.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12203177" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A randomized, double-blind, placebo-controlled trial of acetazolamide for the treatment of elevated intracranial pressure in cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10817706" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Correlation of fluconazole MICs with clinical outcome in cryptococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16135526" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Activity of posaconazole in the treatment of central nervous system fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12715306" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Voriconazole treatment for less-common, emerging, or refractory fungal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27169478" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Isavuconazole Treatment of Cryptococcosis and Dimorphic Mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15181565" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Recombinant interferon- gamma 1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22421244" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Adjunctive interferon-γimmunotherapy for the treatment of HIV-associated cryptococcal meningitis: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10975963" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Inflammatory reactions in HIV-1-infected persons after initiation of highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11737333" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Immune restoration disease after the treatment of immunodeficient HIV-infected patients with highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11997718" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Immune reconstitution inflammatory syndrome: emergence of a unique syndrome during highly active antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792382" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Opportunistic infections occurring during highly active antiretroviral treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15095223" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Immune reconstitution in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16354748" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Immune reconstitution inflammatory syndrome: more answers, more questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18317001" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Incidence and risk factors for the immune reconstitution inflammatory syndrome in HIV patients in South Africa: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20334848" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15958835" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Incidence and risk factors of immune reconstitution inflammatory syndrome complicating HIV-associated cryptococcosis in France.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19365271" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Immune reconstitution inflammatory syndrome in HIV-associated cryptococcal meningitis: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21253011" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clinical features and serum biomarkers in HIV immune reconstitution inflammatory syndrome after cryptococcal meningitis: a prospective cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21029993" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Cryptococcal immune reconstitution inflammatory syndrome in HIV-1-infected individuals: proposed clinical case definitions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15496623" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26863355" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Adjunctive Dexamethasone in HIV-Associated Cryptococcal Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20001539" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Treatment of HIV-related inflammatory cerebral cryptococcoma with adalimumab.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
